We are delighted to announce that Nanordica has done extensive medical research and testing to develop a new generation wound dressing that will solve the problem of hundreds of millions of people every year. Nanordica is an alumnus of the Startup Incubator and we plan to continue working with them. Started from the Tehnopol Startup Incubator and the National Institute of Chemical Physics and Biological Physics, Nanordica Medical OÜ is an R&D company founded by Estonian researchers with the aim to launch highly effective antibacterial wound dressings to the market comprising new nano-based advanced antibacterial technology. Wound infections are widespread and irreparable wounds lead to a significant decline in the patient’s quality of life. The products currently in use are not effective enough in treating wound infections and this problem needs to be addressed. Preclinical studies suggest that the wound patch developed and patented by Nanordica is several times more efficient than products on the market and is effective against a wide array of microbes (including antibiotic-resistant strains such as Staphylococcus aureus MRSA). Next, in collaboration with the North-Estonian Regional Hospital a clinical study will be conducted to gain proof that Nanordica Medical OÜ wound dressing is also effective for patients with poorly healing infected wounds. A wound infection is a presence of pathogenic bacteria in a wound that causes a significant decline in a patient’s quality of life. In particularly severe cases, incurable wound infection can lead to the limb amputation, of which approximately 12% is fatal. The wound dressings manufactured by Nanordica Medical have different layers and a skin contact layer with fibers comprising antibacterial nanoparticles. The special feature of the product is the combination of fiber materials and nanoparticles. The required amount of antimicrobial agents is incorporated into the fibers and, due to their special textile properties, a contact is made between the microbes and the nanoparticles. This technology helps to fight bacteria more efficiently than the previously known products. The materials of the wound dressings developed by Nanordica Medical are environmentally friendly and breathable. Due to the processes of clinical trial and CE marking, a new Nanordica wound dressing should be available in Europe and the US markets by 2024 at the latest. (On the picture are the Co-founders of Nanordica: Taavi Lipstok, Anna-Liisa Kubo, Olesja Bondarenko and Grigory Vasiliev )